Cagrilintide

Quickstart Highlights

Cagrilintide is a long‑acting acylated analogue of the pancreatic hormone amylin, designed for once‑weekly subcutaneous administration. It activates central amylin receptors to promote satiety, slow gastric emptying, and reduce food intake. In phase 2 and phase 3 trials, cagrilintide produced dose‑dependent weight loss with a predominantly gastrointestinal side‑effect profile.

• Reconstitute: Add 1.0 mL BAC water per labelled 10 mg vial; calculations assume a final volume of 1.0 mL and nominal concentration of 10 mg/mL.
• Typical weekly range: 0.3–2.4 mg once weekly (4-week titration steps over 12 weeks); 4.5 mg is a clinical-trial upper arm, not a target.
• Scale conversion: At 10 mg/mL, 1 U-100 unit = 0.01 mL = 100 mcg. Confirm actual device markings; this arithmetic does not establish measurement accuracy.
• Storage: Lyophilized: store frozen at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F) and use within 30 days.

Protocol Overview

Concise summary of the once‑weekly regimen.

• Goal: Support satiety, reduce food intake, and promote weight management over time.
• Schedule: Weekly subcutaneous injections: 12-week titration, then continuous maintenance at 2.4 mg.
• Dose Range: 0.3–2.4 mg weekly, stepped every 4 weeks; 4.5 mg is a clinical-trial upper arm, not a target.
• Reconstitution: 1.0 mL BAC per labelled 10 mg vial; nominal 10 mg/mL under the stated final-volume assumption.
• Storage: Lyophilized frozen; reconstituted refrigerated; avoid repeated freeze–thaw cycles.

Dosing Protocol

Suggested weekly titration approach based on the Phase 2 and Phase 3 trial designs.

• Start: 0.3 mg weekly for the first 4 weeks to assess tolerability.
• Escalate: Double the dose every 4 weeks (0.3 → 0.6 → 1.2 → 2.4 mg) as tolerated; hold a step longer if nausea persists.
• Target: 2.4 mg weekly from Week 13; maintain. Do not exceed 2.4 mg outside a supervised setting.
• Frequency: Once per week (subcutaneous) on the same day each week.
• Timing: Any consistent time; rotate injection sites.

Storage Instructions

Proper storage preserves peptide integrity and potency.

• Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions; minimize moisture exposure.
• Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within 30 days and avoid freeze–thaw cycles.
• Allow vials to reach room temperature before opening to reduce condensation uptake.

Important Notes

Practical considerations for consistency and tolerability.

• Use new sterile syringes for each injection; dispose in a sharps container.
• Rotate injection sites (abdomen, thighs, upper arms) weekly to reduce local irritation.
• Gradual dose escalation minimizes gastrointestinal side effects such as nausea.
• Document weekly dose, injection site, and any adverse effects to maintain consistency.
• The 4.5 mg example is 0.45 mL at the stated concentration. Verify actual device specifications.

How This Works

Cagrilintide is an acylated, long‑acting analogue of amylin—a hormone co‑secreted with insulin from pancreatic beta cells. Native amylin promotes satiation, slows gastric emptying, and inhibits postprandial glucagon secretion. By acting on central amylin receptors (particularly in the area postrema and hindbrain), cagrilintide reduces appetite and energy intake. Lipid modifications extend its half‑life to approximately 160–195 hours, enabling once‑weekly dosing.

Potential Benefits & Side Effects

Observations from phase 2 and phase 3 clinical trials.

• Weight reduction: In the phase 2 trial, cagrilintide 4.5 mg weekly produced approximately 10.8% body weight loss over 26 weeks versus 3.0% with placebo.
• Combination therapy: When combined with semaglutide 2.4 mg (CagriSema), phase 3 REDEFINE trials showed approximately 20% weight loss at 68 weeks, exceeding results with either agent alone.
• Dose‑dependent efficacy: Higher doses (2.4–4.5 mg) demonstrate greater weight loss than lower doses (0.3–1.2 mg).
• Side effects: Primarily gastrointestinal—nausea, vomiting, diarrhea, and constipation—which are generally mild‑to‑moderate and transient. Gradual titration helps minimize these effects.
• Injection‑site reactions: Occasional mild redness or irritation at subcutaneous injection sites.

Lifestyle Factors

Complementary strategies for optimal outcomes.

• Pair with a balanced, protein‑forward diet tailored to individual energy needs.
• Combine resistance training and aerobic activity to support metabolic health and preserve lean mass.
• Prioritize adequate sleep (7–9 hours) and stress management for adherence and recovery.
• Monitor hydration and electrolytes, especially if experiencing gastrointestinal side effects.

Injection Technique

General subcutaneous guidance from clinical best‑practice resources.

• Clean the vial stopper and skin with alcohol; allow to air dry completely.
• Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue.
• Do not aspirate for subcutaneous injections; inject slowly and steadily.
• Hold for 5–10 seconds before withdrawing the needle to ensure complete delivery.
• Rotate sites systematically (abdomen, thighs, upper arms) each week to avoid lipohypertrophy.

Recommended Source

Note: Product availability and specifications subject to change. Verify current product details on supplier website.
Shop at Amino Labs